Table 2.
Susceptibility Ratio to Cefiderocol and Comparators of Carbapenem-resistant Isolates From the SIDERO-CR-2014/2016 Study
| Ratio of Susceptible Strainsa, (%) | |||||
|---|---|---|---|---|---|
| Species (No. of Strains) | Cefiderocol | Ceftazidime-avibactam | Ceftolozane-tazobactam | Ciprofloxacin | Colistin |
| Carbapenem-nonsusceptible strainsb | |||||
| Enterobacteriaceae (1022) | 97.0 | 77.0 | 1.7 | 11.5 | 77.8c |
| Pseudomonas aeruginosa (262) | 99.2 | 36.3 | 24.1 | 1.2 | 99.6 |
| Acinetobacter baumannii (368) | 90.9 | NA | NA | 0 | 94.6 |
| Stenotrophomonas maltophilia (217) | 100e | NA | NA | NA | NA |
Source: Adapted from [23].
Abbreviation: NA, susceptibility breakpoints not available.
aRatio of susceptible strains (%) was calculated using the following minimum inhibitory concentration (MIC) criteria: cefiderocol MIC ≤4 µg/mL; ceftazidime-avibactam MIC ≤8 µg/mL; ceftolozane-tazobactam MIC ≤2 µg/mL for Enterobacteriaceae, ≤4 µg/mL for nonfermenters; ciprofloxacin MIC ≤1 µg/mL; colistin MIC ≤2 µg/mL.
bCarbapenem-nonsusceptible strain was defined as meropenem MIC ≥2 µg/mL for Enterobacteriaceae, ≥4 µg/mL for nonfermenters.
cIncludes 39 Serratia species that are intrinsically resistant to colistin.